Related Experiment Video
Updated: Jan 5, 2026
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
15.5K
Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Samira Bahrami1,2, Bahram Kazemi1,2, Hakimeh Zali3
1Biotechnology Department, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Current Molecular Pharmacology
|October 18, 2019
Summary
This study identifies potential new targets for bladder cancer therapy by analyzing proteomic data. Researchers found several membrane proteins that could be targeted by antibody-based treatments to improve patient outcomes.
Area of Science:
- Oncology
- Proteomics
- Immunotherapy
Background:
- Bladder cancer is a significant cause of cancer death, with high recurrence rates.
- Current chemotherapy for muscle-invasive bladder cancer (MIBC) has limited survival benefits.
- Novel therapeutic strategies, particularly antibody-based therapies, are crucial for improving bladder cancer treatment.
Purpose of the Study:
- To identify potential cell surface antigen targets for bladder cancer therapy.
- To leverage proteomic data for discovering new therapeutic targets.
Main Methods:
- Utilized isobaric tag for relative and absolute quantitation (iTRAQ) and reverse-phase protein array (RPPA) analyses.
- Integrated proteomic data to identify 331 unique overexpressed proteins.
- Employed Gene Ontology (GO), PANTHER, and Human Protein Atlas databases for protein analysis and target selection.
Main Results:
- Identified several membrane proteins as potential therapeutic targets for bladder cancer.
- Key targets include Epidermal growth factor receptor (EGFR), Her2, Kinase insert domain receptor (KDR), Heat shock protein 60 (HSP60), HSP90, Transferrin receptor (TFRC), Activin A Receptor Like Type 1 (ACVRL1), and cadherin 2 (CDH2).
- These targets have been previously investigated for antibody-based treatments in other cancers.
Conclusions:
- Selected membrane proteins represent promising targets for antibody-based bladder cancer therapies.
- Monoclonal antibodies and inhibitors targeting these proteins show potential for treating bladder cancer.
- Combination therapies involving these agents may offer improved treatment efficacy.
